Company Encyclopedia
View More
name
ACROBIOSYSTEMS
301080.SZ
Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization. The company was founded in 2010 and is based in Beijing, China.
1.601 T
301080.SZMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
BiotechnologyIndustry
Industry Ranking7/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.63%C
    • Profit Margin21.75%A
    • Gross Margin103.09%A
  • Growth ScoreB
    • Revenue YoY33.63%A
    • Net Profit YoY58.61%B
    • Total Assets YoY4.59%C
    • Net Assets YoY2.76%C
  • Cash ScoreB
    • Cash Flow Margin459.88%C
    • OCF YoY33.63%A
  • Operating ScoreD
    • Turnover0.28D
  • Debt ScoreA
    • Gearing Ratio10.00%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Founder Securities: A new round of upward movement in the pharmaceutical industry has begun, focusing on early research and the new trend of CRO industry outsourcing

    Fangzheng Securities released a research report indicating that the pharmaceutical and biotechnology industry has entered a new upward cycle, and the recovery of financing for innovative drugs will drive the growth of clinical projects. It is recommended to pay attention to upstream companies in the biotechnology sector with strong overseas capabilities and the early research CRO industry chain, believing that the domestic early research industry chain will benefit from the recovery of overseas demand. It is expected that the price of experimental monkeys will remain stable with a slight increase in the short term, and the prospects for upstream biological products going overseas are broad

    Zhitong·
    HK
    02315
    -1.41%
    SZ
    301080
    -1.32%
    SZ
    300759
    -1.80%
    Zhitong·
    HK
    02315
    -1.41%
    SZ
    301080
    -1.32%
    SZ
    300759
    -1.80%

    New Stock News | ACROBIOSYSTEMS plans Hong Kong IPO with revenue exceeding 600 million yuan in the first three quarters

    ACROBIOSYSTEMS announced on October 29th its plan to conduct an H-share IPO on the Hong Kong Stock Exchange to promote its internationalization strategy. The company's revenue for the first three quarters reached 613 million yuan, a year-on-year increase of 32.3%; the net profit attributable to the parent company was 132 million yuan, a year-on-year increase of 58.6%. The company focuses on biotechnology, with its main business including the research and development, production, and sales of biopharmaceuticals, involving drug development and optimization for various diseases

    Zhitong·
    SZ
    301080
    -1.32%
    Zhitong·
    SZ
    301080
    -1.32%

    ACROBIOSYSTEMS: Plans to issue shares overseas and list on the Hong Kong Stock Exchange Limited

    ACROBIOSYSTEMS plans to hold a meeting on October 28, 2025, to review the relevant preparations for issuing shares overseas and listing on the Hong Kong Stock Exchange. This move aims to promote its internationalization strategy, enhance its overseas business layout, broaden financing channels, and improve international visibility and competitiveness. Relevant details have yet to be determined and need to be submitted for review by the board of directors and shareholders' meeting, as well as obtaining approval from government and regulatory agencies, which carries uncertainties, and investors should be aware of the risks

    Zhitong·
    SZ
    301080
    -1.32%
    Zhitong·
    SZ
    301080
    -1.32%

    ACROBIOSYSTEMS: The net profit for the third quarter was 48.6224 million yuan, a year-on-year increase of 81.46%

    ACROBIOSYSTEMS announced that its revenue for the third quarter was 226 million yuan, a year-on-year increase of 37.50%; net profit was 48.6224 million yuan, a year-on-year increase of 81.46%. Revenue for the first three quarters was 613 million yuan, a year-on-year increase of 32.26%; net profit was 132 million yuan, a year-on-year increase of 58.61%

    Zhitong·
    SZ
    301080
    -1.32%
    Zhitong·
    SZ
    301080
    -1.32%

    ACROBIOSYSTEMS: Plans to cancel a total of 670,500 shares

    ACROBIOSYSTEMS announced that the company plans to change the use of the remaining 57,803 shares from the first phase of repurchased shares in the special securities account from "for employee stock ownership plans or equity incentives" to "for cancellation and corresponding reduction of registered capital," and will proceed with the cancellation procedures for 612,700 shares in the second phase of repurchased shares in the special securities account as planned. The company intends to cancel a total of 670,500 shares involved in the first and second phase repurchase plans. After the cancellation is completed, the company's total share capital will be reduced from 168 million shares to 167 million shares

    Zhitong·
    SZ
    301080
    -1.32%
    Zhitong·
    SZ
    301080
    -1.32%